GTBP Common Stock vs Accounts Payable Analysis

GTBP Stock

USD 2.94 0.07 2.33%

GT Biopharma financial indicator trend analysis is much more than just examining GT Biopharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GT Biopharma is a good investment. Please check the relationship between GT Biopharma Common Stock and its Accounts Payable accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.

Common Stock vs Accounts Payable

Common Stock vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GT Biopharma Common Stock account and Accounts Payable. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between GT Biopharma's Common Stock and Accounts Payable is -0.07. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of GT Biopharma, assuming nothing else is changed. The correlation between historical values of GT Biopharma's Common Stock and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of GT Biopharma are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Common Stock i.e., GT Biopharma's Common Stock and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.07

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Common Stock

Accounts Payable

An accounting item on the balance sheet that represents GT Biopharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of GT Biopharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from GT Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GT Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.At this time, GT Biopharma's Selling General Administrative is relatively stable compared to the past year. As of 10/31/2024, Issuance Of Capital Stock is likely to grow to about 10.2 M, while Sales General And Administrative To Revenue is likely to drop 2.17.

	2023	2024 (projected)
Total Operating Expenses	13.6M	10.7M
Cost Of Revenue	3.6K	3.4K

Total Operating Expenses Cost Of Revenue

GT Biopharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Non Current Liabilities Total	Short Long Term Debt Total	Short Term Debt	Other Assets	Preferred Stock Total Equity
Total Assets		-0.14	-0.22	0.97	-0.15	-0.21	-0.03	0.15	-0.01	0.99	-0.06	-0.02	-0.16	-0.06	-0.07	-0.18	0.26	-0.22	-0.15	-0.03	-0.13	-0.1	-0.23	-0.22	-0.11	-0.31
Other Current Liab	-0.14		0.83	-0.32	-0.15	0.22	0.19	-0.22	-0.21	-0.11	-0.14	-0.19	-0.16	-0.13	-0.09	-0.21	-0.26	0.83	-0.15	-0.19	-0.19	-0.1	0.15	0.13	-0.12	-0.23
Total Current Liabilities	-0.22	0.83		-0.43	-0.29	0.64	-0.01	-0.14	-0.03	-0.19	-0.24	-0.18	-0.34	-0.26	-0.2	0.22	-0.1	1.0	-0.29	-0.18	-0.34	0.39	0.66	0.64	-0.25	-0.04
Total Stockholder Equity	0.97	-0.32	-0.43		-0.07	-0.34	-0.03	0.17	0.0	0.96	0.0	0.02	-0.07	0.0	-0.02	-0.22	0.27	-0.43	-0.07	0.01	-0.05	-0.18	-0.36	-0.35	-0.04	-0.28
Property Plant And Equipment Net	-0.15	-0.15	-0.29	-0.07		-0.25	-0.16	-0.1	0.15	-0.16	0.71	0.1	0.56	0.69	0.69	0.13	0.14	-0.29	1.0	0.12	0.46	-0.09	-0.19	-0.19	0.67	0.64
Net Debt	-0.21	0.22	0.64	-0.34	-0.25		0.04	-0.43	-0.32	-0.12	-0.19	-0.57	-0.24	-0.21	-0.17	0.38	-0.12	0.63	-0.25	-0.58	-0.41	0.59	0.94	0.94	-0.2	0.03
Retained Earnings	-0.03	0.19	-0.01	-0.03	-0.16	0.04		-0.73	-0.56	0.07	0.27	-0.69	0.52	0.28	0.3	-0.55	-0.97	-0.01	-0.16	-0.68	0.37	-0.41	-0.15	-0.16	0.37	-0.54
Accounts Payable	0.15	-0.22	-0.14	0.17	-0.1	-0.43	-0.73		0.71	0.02	-0.23	0.93	-0.41	-0.24	-0.25	0.33	0.75	-0.14	-0.1	0.93	-0.07	0.16	-0.21	-0.2	-0.3	0.27
Cash	-0.01	-0.21	-0.03	0.0	0.15	-0.32	-0.56	0.71		-0.13	0.07	0.83	-0.08	0.05	0.06	0.56	0.52	-0.03	0.15	0.84	0.24	0.43	0.03	0.03	0.02	0.55
Non Current Assets Total	0.99	-0.11	-0.19	0.96	-0.16	-0.12	0.07	0.02	-0.13		-0.05	-0.17	-0.13	-0.06	-0.06	-0.23	0.17	-0.19	-0.16	-0.17	-0.15	-0.11	-0.18	-0.17	-0.09	-0.37
Non Currrent Assets Other	-0.06	-0.14	-0.24	0.0	0.71	-0.19	0.27	-0.23	0.07	-0.05		-0.07	0.92	1.0	0.99	0.1	-0.26	-0.24	0.71	-0.04	0.86	-0.09	-0.14	-0.14	0.99	0.49
Cash And Short Term Investments	-0.02	-0.19	-0.18	0.02	0.1	-0.57	-0.69	0.93	0.83	-0.17	-0.07		-0.22	-0.07	-0.09	0.32	0.67	-0.18	0.1	1.0	0.11	0.1	-0.31	-0.3	-0.12	0.4
Common Stock Total Equity	-0.16	-0.16	-0.34	-0.07	0.56	-0.24	0.52	-0.41	-0.08	-0.13	0.92	-0.22		0.92	0.92	-0.06	-0.52	-0.34	0.56	-0.19	0.9	-0.2	-0.25	-0.26	0.96	0.28
Common Stock Shares Outstanding	-0.06	-0.13	-0.26	0.0	0.69	-0.21	0.28	-0.24	0.05	-0.06	1.0	-0.07	0.92		0.99	0.04	-0.27	-0.26	0.69	-0.05	0.86	-0.15	-0.17	-0.18	0.99	0.47
Inventory	-0.07	-0.09	-0.2	-0.02	0.69	-0.17	0.3	-0.25	0.06	-0.06	0.99	-0.09	0.92	0.99		0.08	-0.29	-0.2	0.69	-0.06	0.86	-0.1	-0.12	-0.13	0.98	0.46
Other Current Assets	-0.18	-0.21	0.22	-0.22	0.13	0.38	-0.55	0.33	0.56	-0.23	0.1	0.32	-0.06	0.04	0.08		0.46	0.22	0.13	0.33	0.07	0.94	0.61	0.61	0.04	0.64
Other Stockholder Equity	0.26	-0.26	-0.1	0.27	0.14	-0.12	-0.97	0.75	0.52	0.17	-0.26	0.67	-0.52	-0.27	-0.29	0.46		-0.1	0.14	0.66	-0.38	0.33	0.04	0.06	-0.36	0.43
Total Liab	-0.22	0.83	1.0	-0.43	-0.29	0.63	-0.01	-0.14	-0.03	-0.19	-0.24	-0.18	-0.34	-0.26	-0.2	0.22	-0.1		-0.29	-0.18	-0.34	0.38	0.65	0.64	-0.25	-0.04
Property Plant And Equipment Gross	-0.15	-0.15	-0.29	-0.07	1.0	-0.25	-0.16	-0.1	0.15	-0.16	0.71	0.1	0.56	0.69	0.69	0.13	0.14	-0.29		0.12	0.46	-0.09	-0.19	-0.19	0.67	0.64
Total Current Assets	-0.03	-0.19	-0.18	0.01	0.12	-0.58	-0.68	0.93	0.84	-0.17	-0.04	1.0	-0.19	-0.05	-0.06	0.33	0.66	-0.18	0.12		0.13	0.11	-0.31	-0.3	-0.09	0.42
Common Stock	-0.13	-0.19	-0.34	-0.05	0.46	-0.41	0.37	-0.07	0.24	-0.15	0.86	0.11	0.9	0.86	0.86	0.07	-0.38	-0.34	0.46	0.13		-0.12	-0.31	-0.31	0.88	0.38
Non Current Liabilities Total	-0.1	-0.1	0.39	-0.18	-0.09	0.59	-0.41	0.16	0.43	-0.11	-0.09	0.1	-0.2	-0.15	-0.1	0.94	0.33	0.38	-0.09	0.11	-0.12		0.78	0.78	-0.13	0.42
Short Long Term Debt Total	-0.23	0.15	0.66	-0.36	-0.19	0.94	-0.15	-0.21	0.03	-0.18	-0.14	-0.31	-0.25	-0.17	-0.12	0.61	0.04	0.65	-0.19	-0.31	-0.31	0.78		1.0	-0.17	0.25
Short Term Debt	-0.22	0.13	0.64	-0.35	-0.19	0.94	-0.16	-0.2	0.03	-0.17	-0.14	-0.3	-0.26	-0.18	-0.13	0.61	0.06	0.64	-0.19	-0.3	-0.31	0.78	1.0		-0.18	0.25
Other Assets	-0.11	-0.12	-0.25	-0.04	0.67	-0.2	0.37	-0.3	0.02	-0.09	0.99	-0.12	0.96	0.99	0.98	0.04	-0.36	-0.25	0.67	-0.09	0.88	-0.13	-0.17	-0.18		0.42
Preferred Stock Total Equity	-0.31	-0.23	-0.04	-0.28	0.64	0.03	-0.54	0.27	0.55	-0.37	0.49	0.4	0.28	0.47	0.46	0.64	0.43	-0.04	0.64	0.42	0.38	0.42	0.25	0.25	0.42

Click cells to compare fundamentals

GT Biopharma Account Relationship Matchups

GT Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	396K	5.7M	32.2M	16.7M	14.1M	13.2M
Other Current Liab	4.4M	383K	138K	1.7M	2.2M	2.3M
Total Current Liabilities	19.7M	35.1M	10.3M	4.9M	6.6M	6.9M
Total Stockholder Equity	(19.1M)	(29.3M)	21.9M	11.7M	7.5M	7.1M
Property Plant And Equipment Net	35K	110K	0.0	165K	53K	50.4K
Net Debt	13.3M	21.0M	(8.9M)	(5.5M)	(1.0M)	(970.0K)
Retained Earnings	(567.3M)	(595.6M)	(653.6M)	(674.5M)	(682.1M)	(648.0M)
Accounts Payable	1.9M	2.2M	8.2M	3.1M	4.3M	4.5M
Cash	28K	5.3M	9.0M	5.7M	1.1M	1.2M
Non Current Assets Total	25.3M	122K	0.0	174K	53K	50.4K
Cash And Short Term Investments	28K	5.3M	32.0M	16.5M	14.0M	14.7M
Common Stock Total Equity	50K	51K	70K	52K	46.8K	44.5K
Common Stock Shares Outstanding	112.8K	146.2K	938.5K	1.1M	1.3M	1.3M
Liabilities And Stockholders Equity	396K	5.7M	32.2M	16.7M	14.1M	13.2M
Other Current Assets	246K	364K	190K	54K	84K	79.8K
Other Stockholder Equity	548.1M	566.3M	673.2M	686.2M	689.5M	724.0M
Total Liab	19.7M	35.1M	10.3M	5.0M	6.6M	7.1M
Property Plant And Equipment Gross	35K	110K	0.0	165K	53K	50.4K
Total Current Assets	274K	5.7M	32.2M	16.6M	14.1M	14.8M
Common Stock	70K	52K	1.1M	33K	1K	950.0
Short Long Term Debt Total	10.8M	13.4M	26.3M	174K	58K	55.1K
Short Term Debt	10.8M	13.4M	26.3M	110K	58K	55.1K
Net Tangible Assets	(13.7M)	(19.1M)	(29.3M)	21.9M	25.2M	26.5M
Short Long Term Debt	31K	10.8M	13.2M	26.3M	35.7K	33.9K
Net Invested Capital	(5.9M)	(2.9M)	21.9M	11.7M	7.5M	7.1M
Net Working Capital	(19.4M)	(29.4M)	21.9M	11.6M	7.4M	7.8M
Capital Stock	73K	55K	1.1M	34K	2K	1.9K

Pair Trading with GT Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against GTBP Stock

0.5	MLAB	Mesa Laboratories	Pair Corr
0.37	MRVI	Maravai Lifesciences	Pair Corr

The ability to find closely correlated positions to GT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GT Biopharma to buy it.

The correlation of GT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GT Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for GT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for GTBP Stock Analysis

When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC